Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomerica (BMRA) EBITDA (2016 - 2026)

Biomerica's EBITDA history spans 17 years, with the latest figure at -$1.3 million for Q1 2026.

  • Quarterly results put EBITDA at -$1.3 million for Q1 2026, down 12.71% from a year ago — trailing twelve months through Feb 2026 was -$4.2 million (up 14.32% YoY), and the annual figure for FY2025 was -$5.0 million, up 16.65%.
  • EBITDA for Q1 2026 was -$1.3 million at Biomerica, up from -$1.3 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $4000.0 in Q3 2025 to a low of -$2.1 million in Q3 2022.
  • The 5-year median for EBITDA is -$1.4 million (2024), against an average of -$1.3 million.
  • The sharpest move saw EBITDA crashed 1460.36% in 2023, then surged 100.3% in 2025.
  • Year by year, EBITDA stood at -$1.6 million in 2022, then rose by 7.83% to -$1.5 million in 2023, then surged by 36.7% to -$954000.0 in 2024, then plummeted by 38.47% to -$1.3 million in 2025, then increased by 0.68% to -$1.3 million in 2026.
  • According to Business Quant data, EBITDA over the past three periods came in at -$1.3 million, -$1.3 million, and $4000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.